Now Reading
Accelerating Global Access
Our company is collaborating with a range of partners to enable access for patients around the world
Accelerating Global Access
Our company is collaborating with a range of partners to enable access for patients around the world
Published 12-13-21
Submitted by Merck & Co., Inc.
At the outset of our research efforts for COVID-19, our company made clear its commitment to make any vaccine or medicine we develop for this pandemic broadly accessible.
Here’s how we have been working to fulfill that commitment.
Merck & Co., Inc.
Merck & Co., Inc.
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
More from Merck & Co., Inc.